News Roche pays $1.7 billion for cancer specialist Ignyta Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta.
News After surging on lung cancer data, Ignyta looks to raise $16... San Diego based biotech firm Ignyta is capping off a week of success with a public stock offering t
News J&J's nipocalimab fast-tracked for Sjogren's disease Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
